Skip header and navigation

Refine By

197 records – page 1 of 20.

The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.

https://arctichealth.org/en/permalink/ahliterature173682
Source
Eur Urol. 2005 Oct;48(4):679-85
Publication Type
Article
Date
Oct-2005
Author
Yvonne L Giwercman
Per-Anders Abrahamsson
Aleksander Giwercman
Virgil Gadaleanu
Göran Ahlgren
Author Affiliation
Department of Urology, Malmö University Hospital, Lund University, Wallenberg Laboratory, entrance 46, SE - 205 02 Malmö, Sweden. yvonne.giwercman@kir.mas.lu.se
Source
Eur Urol. 2005 Oct;48(4):679-85
Date
Oct-2005
Language
English
Publication Type
Article
Keywords
3-Oxo-5-alpha-Steroid 4-Dehydrogenase - blood - genetics
Aged
Alanine
Alleles
Arginine
Case-Control Studies
Dihydrotestosterone - blood
Disease Progression
Follow-Up Studies
Genetic Predisposition to Disease
Genotype
Glutamine
Humans
Leucine
Luteinizing Hormone - blood
Male
Middle Aged
Point Mutation
Polymorphism, Genetic
Prostatic Hyperplasia - blood - epidemiology - genetics
Prostatic Neoplasms - blood - epidemiology - genetics
Receptors, Androgen - blood - genetics
Risk factors
Sex Hormone-Binding Globulin - metabolism
Sweden - epidemiology
Terminal Repeat Sequences
Testosterone - blood
Threonine
Tumor Markers, Biological - blood
Valine
Abstract
To compare men with prostate disease with those from the general population regarding polymorphisms in the androgen receptor gene and in the 5alpha-reductase II (SRD5A2) gene.
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
The SRD5A2 high-activity allele variants A49T AT and V89L LL were more frequent in CaP-patients compared to general population, p=0.026 and p=0.05, respectively. CaP progression was, however, independent of SRD5A2 variants. In contrary, men with GGN
PubMed ID
16039774 View in PubMed
Less detail

Aminoterminal propeptide of type III procollagen in ovarian cancer. A review.

https://arctichealth.org/en/permalink/ahliterature24596
Source
Acta Obstet Gynecol Scand Suppl. 1992;155:99-103
Publication Type
Article
Date
1992
Author
L. Risteli
J. Risteli
U. Puistola
C. Tomás
G G Zhu
A. Kauppila
Author Affiliation
Department of Medical Biochemistry, University of Oulu, Finland.
Source
Acta Obstet Gynecol Scand Suppl. 1992;155:99-103
Date
1992
Language
English
Publication Type
Article
Keywords
Antigens, Tumor-Associated, Carbohydrate - analysis
Endometrial Neoplasms - diagnosis
Female
Humans
Ovarian Neoplasms - blood - diagnosis
Peptide Fragments - blood
Procollagen - blood
Research Support, Non-U.S. Gov't
Tumor Markers, Biological - blood
Uterine Cervical Neoplasms - diagnosis
Abstract
The concentration of the aminoterminal propeptide of type III procollagen (PIIINP) in serum is a measure of the activity of the metabolism of type III collagen, which is a major constituent of soft connective tissues and of the connective tissue stroma of solid tumours. In advanced ovarian carcinoma, serum PIIINP serves as a tumour-associated antigen, its changes reflecting and preceding changes in the clinical behaviour of the malignancy. Elevated values of serum PIIINP are also observed in endometrial and cervical malignancies, though less frequently than in ovarian tumours. Very high concentrations of PIIINP are found in ovarian carcinoma ascites, suggesting an ongoing fibro-proliferative reaction in the peritoneal cavity as a response to the tumour.
PubMed ID
1502898 View in PubMed
Less detail

Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.

https://arctichealth.org/en/permalink/ahliterature3982
Source
Int J Cancer. 2000 Apr 1;86(1):71-5
Publication Type
Article
Date
Apr-1-2000
Author
R. Dardari
M. Khyatti
A. Benider
H. Jouhadi
A. Kahlain
C. Cochet
A. Mansouri
B. El Gueddari
A. Benslimane
I. Joab
Author Affiliation
Institut Pasteur du Maroc, Casablanca, Morocco.
Source
Int J Cancer. 2000 Apr 1;86(1):71-5
Date
Apr-1-2000
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Antibodies, Neoplasm - blood - immunology
Antibodies, Viral - blood - immunology
Antibody Specificity
Antigens, Viral - immunology
Capsid - immunology
Child
Child, Preschool
Comparative Study
DNA-Binding Proteins - immunology
Female
Herpesvirus 4, Human - immunology
Humans
Immunoglobulin A - blood - immunology
Immunoglobulin G - blood - immunology
Male
Nasopharyngeal Neoplasms - blood - immunology - pathology - virology
Neoplasm Staging
Research Support, Non-U.S. Gov't
Trans-Activators - immunology
Tumor Markers, Biological - blood - immunology
Viral Proteins - immunology
Abstract
Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) generally occurs in adults, especially in high-prevalence populations such as the Chinese and Eskimos. In Maghrebian populations, young patients affected with this malignancy represent 25% of the total NPC cases. In adults with NPC, relatively high titers of IgA antibodies to the EBV viral capsid antigen (VCA) and early antigen (EA) represent important markers. However, nearly 50% of young NPC patients are negative for IgA-anti-VCA and -EA or exhibit very low titers of these antibodies. We report here that 92% of sera from young NPC patients negative for IgA-EA and 89% of those negative for IgA-VCA were positive for IgG antibodies to the EBV transactivator protein (ZEBRA) at very high titers. Our results show that in young patients with NPC these antibodies represent the most reliable marker for diagnosis and prognosis, particularly when compared with conventional NPC markers, i.e., IgA-VCA (58%) and anti-EA (25%). The titers of IgG-ZEBRA antibodies increased along with lymph node involvement only in the young patient group, suggesting a prognostic value of this marker in this patient group.
PubMed ID
10728597 View in PubMed
Less detail

ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.

https://arctichealth.org/en/permalink/ahliterature173303
Source
BJU Int. 2005 Sep;96(4):508-13
Publication Type
Article
Date
Sep-2005
Author
Tomasz M Beer
Author Affiliation
Department of Medicine, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland 97239, USA. beert@ohsu.edu
Source
BJU Int. 2005 Sep;96(4):508-13
Date
Sep-2005
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Antineoplastic Agents, Phytogenic - therapeutic use
Calcitriol - therapeutic use
Canada
Disease-Free Survival
Double-Blind Method
Drug Administration Schedule
Humans
Male
Middle Aged
Placebos
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood - drug therapy - mortality
Survival Rate
Taxoids - therapeutic use
Tumor Markers, Biological - blood
United States
Abstract
ASCENT, the Androgen-Independent Prostate Cancer (AIPC) Study of Calcitriol Enhancing Taxotere, is a double-blind, placebo-controlled randomized clinical trial designed to determine if DN-101, a high-dose oral formulation of calcitriol designed for cancer therapy, significantly increases the proportion of patients who have > 50% reduction in serum prostate-specific antigen (PSA) levels in response to docetaxel. The secondary goals of ASCENT are to evaluate the effect of DN-101 combined with docetaxel on PSA progression-free survival, tumour response rate in measurable disease, tumour progression-free survival, skeletal morbidity-free survival, clinical progression-free survival, and overall survival, and to examine the safety and tolerability of DN-101 combined with docetaxel. ASCENT builds on phase I work showing that weekly dosing allows substantial dose-escalation of calcitriol, the natural ligand for the vitamin D receptor, and on phase II work that suggested that adding weekly high-dose 'pulse' calcitriol may enhance the activity of weekly docetaxel in patients with AIPC. The preclinical rationale for calcitriol and its combination with docetaxel for prostate cancer therapy is reviewed, as are the key clinical trials that led to the development of ASCENT. The ASCENT design and its strengths and limitations are presented.
PubMed ID
16104901 View in PubMed
Less detail

Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study.

https://arctichealth.org/en/permalink/ahliterature137306
Source
Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):428-37
Publication Type
Article
Date
Mar-2011
Author
Mieke Van Hemelrijck
Lars Holmberg
Hans Garmo
Niklas Hammar
Göran Walldius
Elisa Binda
Mats Lambe
Ingmar Jungner
Author Affiliation
Cancer Epidemiology Group, Division of Cancer Studies, School of Medicine, King's College London, 3rd Floor, Bermondsey Wing, Guy's Hospital, London SE1 9RT, United Kingdom. mieke.vanhemelrijck@kcl.ac.uk
Source
Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):428-37
Date
Mar-2011
Language
English
Publication Type
Article
Keywords
Aged
C-Reactive Protein - metabolism
Cohort Studies
Female
Humans
Leukocytes - metabolism
Male
Middle Aged
Neoplasms - blood
Prospective Studies
Risk factors
Sweden
Tumor Markers, Biological - blood
Abstract
To study levels of C-reactive protein (CRP) and leukocytes, as inflammatory markers, in the context of cancer risk.
From the Apolipoprotein MOrtality RISk (AMORIS) study, we selected 102,749 persons with one measurement and 9,273 persons with three repeated measurements of CRP and leukocytes. Multivariate Cox proportional hazards regression was applied to categories of CRP (50 g/L) and quartiles of leukocytes. An inflammation-based predictive score (IPS) indicated whether someone had CRP levels of more than 10 mg/L combined with leukocytes of more than 10×10(9)/L. Reverse causality was assessed by excluding those with less than 3, 5, or 7 years of follow-up. To analyze repeated measurements of CRP and leukocytes, the repeated IPS (IPSr) was calculated by adding the IPS of each measurement.
In the cohort with one measurement, there was a positive trend between CRP and risk of developing cancer, with the lowest category being the 0.99 (0.92-1.06), 1.28 (1.11-1.47), 1.27 (1.09-1.49), and 1.22 (1.01-1.48) for the second to fifth categories, respectively. This association disappeared when excluding those with follow-up of less than 3, 5, or 7 years. The association between leukocytes and cancer was slightly stronger. In the cohort with repeated measurements, the IPSr was strongly associated with cancer risk: 1.87 (1.33-2.63), 1.51 (0.56-4.06), and 4.46 (1.43-13.87) for IPSr=1, 2, and 3 compared with IPSr=0. The association remained after excluding those with follow-up of less than 1 year.
Our large, prospective cohort study adds evidence for a link between inflammatory markers and cancer risk by using repeated measurements and ascertaining reverse causality.
Notes
Cites: Lancet. 2001 Dec 15;358(9298):2026-3311755609
Cites: Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2714-2218843014
Cites: Nature. 2002 Dec 19-26;420(6917):860-712490959
Cites: Cancer Causes Control. 2009 Feb;20(1):15-2618704713
Cites: J Intern Med. 2009 Feb;265(2):275-8719019184
Cites: Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-619318937
Cites: J Clin Oncol. 2009 May 1;27(13):2217-2419289618
Cites: J Natl Cancer Inst. 2010 Feb 3;102(3):142-320056953
Cites: J Clin Oncol. 2010 Jun 1;28(16):2719-2620421535
Cites: Int J Epidemiol. 2010 Jun;39(3):699-70920338892
Cites: Int J Cancer. 2010 Aug 15;127(4):768-7920518013
Cites: Br J Cancer. 2010 Sep 7;103(6):870-620717110
Cites: Cancer Causes Control. 2010 Oct;21(10):1657-6720533084
Cites: Atherosclerosis. 2010 Nov;213(1):299-30520843515
Cites: Eur J Cancer. 2011 Feb;47(3):404-1220727736
Cites: Cancer. 2011 May 15;117(10):2086-9521523720
Cites: J Clin Invest. 2003 Jun;111(12):1805-1212813013
Cites: Blood Press Suppl. 1992;4:35-421345333
Cites: Clin Chem. 1998 Jun;44(6 Pt 1):1358-619625071
Cites: Clin Chem. 1998 Aug;44(8 Pt 1):1641-99702950
Cites: Cancer Res. 1998 Oct 15;58(20):4673-819788621
Cites: Br J Cancer. 2005 May 23;92(10):1834-615870712
Cites: Crit Rev Oncol Hematol. 2005 Oct;56(1):101-1315979322
Cites: Eur J Cancer. 2006 Apr;42(6):704-716513341
Cites: J Clin Oncol. 2006 Nov 20;24(33):5216-2217114654
Cites: Arch Intern Med. 2007 Sep 24;167(17):1837-4417893304
Cites: Am J Clin Nutr. 2007 Sep;86(3):s843-5718265478
Cites: Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):459-6418542007
Cites: J Intern Med. 2008 Jul;264(1):30-818298486
Cites: Trends Immunol. 2002 Nov;23(11):549-5512401408
PubMed ID
21297038 View in PubMed
Less detail

Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.

https://arctichealth.org/en/permalink/ahliterature106282
Source
Clin Biochem. 2014 Jan;47(1-2):87-91
Publication Type
Article
Date
Jan-2014
Author
Théodora Popovici
Baptiste Moreira
Marie-Hélène Schlageter
Phuong-Nhi Bories
Author Affiliation
Department of Clinical Chemistry, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. Electronic address: theodora.popovici@cch.aphp.fr.
Source
Clin Biochem. 2014 Jan;47(1-2):87-91
Date
Jan-2014
Language
English
Publication Type
Article
Keywords
Chromogranin A - blood
Fluorescent Antibody Technique - methods
Humans
Neuroendocrine Tumors - blood
Reproducibility of Results
Tumor Markers, Biological - blood
Abstract
Chromogranin A (CgA) is the best-characterized biological marker common to neuroendocrine tumours and is therefore recommended for their diagnosis. The measurement of serum CgA is of great importance for reaching an early diagnosis and thus reducing the delay before treatment is instigated. The Kryptor CgA assay is the first fully automated assay available. The aim of this study was to evaluate its analytical performance.
The imprecision and linearity of the Kryptor CgA assay were evaluated. This assay was compared with the Cis Bio CgA RIA assay in 78 serum samples. Its clinical utility was assessed in serum from 229 patients.
The study performed on imprecision of Kryptor measurements showed intra- and inter-run CVs = 5%. The study of linearity showed a satisfactory recovery rate for CgA concentrations up to 1200 µg/L. The Kryptor and RIA assays agreed well on the basis of the cut-off values provided by the two manufacturers. The Bland and Altman plot of the values obtained (range: 20-5560 µg/L) provided a mean difference of -10.1 µg/L (SD: 116). The clinical sensitivities of Kryptor CgA for diagnosis of pheochromocytoma and paraganglioma (n 20) and gastroenteropancreatic NETs (n 17) were respectively 100 and 94%.
The Kryptor assay for CgA shows reliable analytical and clinical characteristics and allows a fast delivery of results.
PubMed ID
24201067 View in PubMed
Less detail

Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules.

https://arctichealth.org/en/permalink/ahliterature98935
Source
Head Neck. 2010 May;32(5):612-8
Publication Type
Article
Date
May-2010
Author
Martin Hasselgren
Laszlo Hegedüs
Christian Godballe
Steen Joop Bonnema
Author Affiliation
Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark.
Source
Head Neck. 2010 May;32(5):612-8
Date
May-2010
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Biopsy, Fine-Needle
Calcitonin - blood
Carcinoma, Medullary - diagnosis
Denmark
Female
Goiter, Nodular - epidemiology - surgery
Humans
Male
Middle Aged
Predictive value of tests
Retrospective Studies
Sensitivity and specificity
Thyroid Gland - pathology
Thyroid Neoplasms - diagnosis
Thyroidectomy
Tumor Markers, Biological - blood
Ultrasonography, Interventional
Young Adult
Abstract
BACKGROUND: Routine measurement of serum calcitonin to detect medullary thyroid carcinoma (MTC) continues to be fiercely debated, although less attention has been paid to the positive predictive value (PPV) of this method. METHODS: We collected data from 959 patients with nontoxic nodular goiter; thyroidectomy was performed in 307 of these patients. RESULTS: Thirty-nine patients had elevated serum calcitonin; 6 of these patients had MTC detected by the initial diagnostic setup. No additional patient in the cohort was registered in the Danish Thyroid Cancer Database, reflecting that all patients with MTC were classified correctly initially. The sensitivity of serum calcitonin for detection of MTC was 100%, the specificity was 95.3%, the positive predictive value was 15.4%, and the negative predictive value was 100%. CONCLUSION: Serum calcitonin has high sensitivity and specificity for detection of MTC. The low PPV might lead to unnecessary thyroid surgery. Thus, the result of serum calcitonin measurement should always be interpreted in the context of other clinical variables.
PubMed ID
19691107 View in PubMed
Less detail

[Benz(a)pyrene antibodies are a marker of carcinogenic load in coal-processing workers]

https://arctichealth.org/en/permalink/ahliterature96898
Source
Gig Sanit. 2010 Mar-Apr;(2):53-6
Publication Type
Article
Author
A N Glushkov
E G Poleniuk
S A Mun
S A Larin
S F Zinchuk
Source
Gig Sanit. 2010 Mar-Apr;(2):53-6
Language
Russian
Publication Type
Article
Keywords
Antibodies - blood - immunology
Benzo(a)pyrene - metabolism
Carcinogens
Coal Mining
Female
Humans
Immunoenzyme Techniques
Male
Neoplasms - blood - immunology
Occupational Exposure - adverse effects
Siberia
Tumor Markers, Biological - blood - immunology
Abstract
The authors studied benz(a)pyrene-specific secretory and serum antibody ratios (Ka) in 249 workers of the Kemerovo Power Station, by applying their modified enzyme immunoassay technique. There were 37 (20.5%) and 4 (5.8%) cases with Ka >2 at the preset immunoassay parameters of the 180 and 69 workers of mainline production and auxiliary units, respectively. A Ka value of >2 was found in 35 (21.6%) of the 162 males and only in 6 (6.9%) of the 87 females of the whole sample, in 29 (26.1%) of the 111 smokers and in 12 (8.7%) of the 138 non-smokers. The technique is proposed to study specific immune reactions and exposure to carcinogens primarily in workers of the enterprises processing coal and other types of fuel.
PubMed ID
20491270 View in PubMed
Less detail

Biomarkers related to one-carbon metabolism as potential risk factors for distal colorectal adenomas.

https://arctichealth.org/en/permalink/ahliterature133548
Source
Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1726-35
Publication Type
Article
Date
Aug-2011
Author
Stefan de Vogel
Jörn Schneede
Per Magne Ueland
Stein Emil Vollset
Klaus Meyer
Ase Fredriksen
Øivind Midttun
Tone Bjørge
Ellen Kampman
Michael Bretthauer
Geir Hoff
Author Affiliation
Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway. Stefan.Vogel@isf.uib.no
Source
Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1726-35
Date
Aug-2011
Language
English
Publication Type
Article
Keywords
Adenoma - blood - epidemiology - genetics - pathology
Betaine - blood
Colorectal Neoplasms - blood - epidemiology - genetics - pathology
Female
Genotype
Humans
Male
Methionine - blood
Middle Aged
Norway - epidemiology
Polymorphism, Genetic
Riboflavin - blood
Risk factors
Tumor Markers, Biological - blood
Vitamin B 6 - blood
Abstract
Efficient one-carbon metabolism, which requires adequate supply of methyl group donors and B-vitamins, may protect against colorectal carcinogenesis. However, plasma folate and vitamins B2 and B12 have inconsistently been associated with colorectal cancer risk, and there have been no previous studies relating plasma concentrations of methionine, choline, and betaine to this outcome.
This study comprised 10,601 individuals, 50 to 64 years of age, participating in the Norwegian Colorectal Cancer Prevention (NORCCAP) screening study. Using logistic regression analyses, we crosssectionally investigated associations between distal colorectal adenoma occurrence-potential precursor lesions of colorectal carcinomas-and plasma concentrations of methyl group donors and B-vitamins, and polymorphisms of genes related to one-carbon metabolism.
Screening revealed 1,809 subjects (17.1%) with at least one adenoma. The occurrence of high-risk adenomas (observed in 421 subjects) was inversely associated with plasma concentrations of methionine (highest versus lowest quartile: odds ratio (OR) = 0.61; 95% confidence interval (CI) = 0.45-0.83), betaine: OR = 0.74; 95% CI = 0.54-1.02, the vitamin B2 form flavin-mononucleotide (FMN): OR = 0.65; 95% CI = 0.49-0.88, and the vitamin B6 form pyridoxal 5'-phosphate (PLP): OR = 0.69; 95% CI = 0.51-0.95, but not with folate, choline, vitamin B12 concentrations, or with the studied polymorphisms. High methionine concentration in combination with high vitamin B2 or B6 concentrations was associated with lower occurrence of high-risk adenomas compared with these factors individually.
High plasma concentrations of methionine and betaine, and vitamins B2 and B6 may reduce risk of developing colorectal adenomas.
In addition to B-vitamins, methyl group donors such as methionine and betaine may play a role in colorectal carcinogenesis.
PubMed ID
21693628 View in PubMed
Less detail

197 records – page 1 of 20.